4.6 Letter

First observation of dupilumab efficacy in an infant with SAM (severe dermatitis, multiple allergies and metabolic wasting) syndrome

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, Research & Experimental

Translational implications of Th17-skewed inflammation due to genetic deficiency of a cadherin stress sensor

Lisa M. Godsel et al.

Summary: Research reveals that genetic deficiency of Dsg1 causes a psoriatic-like inflammatory signature, and treatment with targeted therapy significantly improves skin lesions in patients.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Article Dermatology

A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy

A. S. Paller et al.

Summary: The study evaluated the pharmacokinetics, safety, and efficacy of single-dose dupilumab in children with severe AD aged 6 months to 6 years. The results showed generally good tolerability and substantial reduction in clinical signs/symptoms of AD, with slightly better responses in older children.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Letter Dermatology

Response to dupilumab in two children with Netherton syndrome: Improvement of pruritus and scaling

K. Suessmuth et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Letter Dermatology

Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency

L. H. Frommherz et al.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Review Allergy

Cutaneous barrier dysfunction in allergic diseases

Donald Y. M. Leung et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Letter Medicine, General & Internal

Imbalance in T-Helper 17 Cells and Targeted Therapy in an Infant with SAM-like Syndrome

Angela Hernandez-Martin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)